Bristol Myers Squibb and Celgene named in class action suit over cancer blockbuster Pomalyst
Blue Cross Blue Shield of Louisiana is taking Bristol Myers Squibb to court over what it alleges to be an unlawful monopoly for the cancer blockbuster Pomalyst.
BMS acquired Pomalyst, also known as pomalidomide, in its $74 billion Celgene takeover in 2019. While the drug was first approved in 2013 for patients with multiple myeloma, BMS swung a label expansion the following year to include a rare form of cancer called Kaposi sarcoma. The drug generated nearly $3.5 billion in 2022 sales, according to BMS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.